α1b-干扰素治疗慢性粒细胞白血病Ⅲ期临床试验总结

• 作 者: 薛艳萍 赵耀中 卞寿庚
• 机 构: 中国医学科学院血液学研究所血液病医院
• 出 处: 中国实用内科杂志
• 发表日期: 1998年06期
• 关键词: 慢性粒细胞白血病 α1b-干扰素

采用α１ｂ干扰素联合羟基脲治疗慢性粒细胞白血病（ＣＭＬ）７０例，治疗方法为：α１ｂ干扰素３０×１０６ＩＵ／ｄ，连续皮下或肌肉注射，羟基脲１～３ｇ／ｄ，口服。结果获血液学完全缓解５２９％（３７／７０例），部分缓解４１４％（２９／７０例），总有效率９４３％。此外，５例获Ｐｈ染色体完全转阴。α１ｂ干扰素主要不良反应为发热（占７０％），肌痛（占３０％）。结果初步证实α１ｂ干扰素治疗ＣＭＬ的近期有较好疗效，更适合于合并血小板增多的ＣＭＬ。

Treatment of chronic myelogenous leukemia (CML) with α1binterferon combined with hydroxyurea in 70 patients, treatment method: α1binterferon 30×106IU/d, continuous subcutaneous or intramuscular injection, hydroxyurea 1~3g/d, oral . The results were hematological complete remission 52.9% (37/70 cases), partial remission 41.4% (29/70 cases), the total effective rate of 94. 3%. In addition, 5 patients had completely negative Ph chromosomes. The main adverse reactions of α1binterferon were fever (70%) and myalgia (30%). The results preliminarily confirmed that α1b-interferon has a good therapeutic effect in the treatment of CML in the near future and is more suitable for CML with thrombocytosis.